These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 28195322)
41. Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment. Koga A; Kajihara I; Yamada S; Makino K; Ichihara A; Aoi J; Makino T; Fukushima S; Jinnin M; Ihn H J Dermatol; 2016 May; 43(5):522-5. PubMed ID: 26507968 [TBL] [Abstract][Full Text] [Related]
42. Infliximab for the treatment of adults with psoriasis. Loveman E; Turner D; Hartwell D; Cooper K; Clegg A Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215 [TBL] [Abstract][Full Text] [Related]
43. Pustular psoriasis occurring after total colectomy for ulcerative colitis and relieved by administration of infliximab. Saito K; Ito A; Ishikawa K; Shimada H; Takeo N; Hatano Y; Sugiura K; Akiyama M; Inomata M; Kitano S; Fujiwara S J Dermatol; 2014 Nov; 41(11):1033-4. PubMed ID: 25297877 [No Abstract] [Full Text] [Related]
44. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Gniadecki R; Kragballe K; Dam TN; Skov L Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290 [TBL] [Abstract][Full Text] [Related]
45. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. Wang J; Zhan Q; Zhang L Hum Vaccin Immunother; 2016; 12(2):431-7. PubMed ID: 26528924 [TBL] [Abstract][Full Text] [Related]
46. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133 [TBL] [Abstract][Full Text] [Related]
47. Biological agents in the treatment of psoriasis. Tzu J; Krulig E; Cardenas V; Kerdel FA G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073 [TBL] [Abstract][Full Text] [Related]
49. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword. Gottlieb AB Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570 [No Abstract] [Full Text] [Related]
50. Two years of experience with etanercept in recalcitrant psoriasis. Ahmad K; Rogers S Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393 [TBL] [Abstract][Full Text] [Related]
51. Infliximab: efficacy in psoriasis. Arsiwala S Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692 [TBL] [Abstract][Full Text] [Related]
52. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. Bissonnette R; Maari C; Barber K; Lynde CW; Vender R J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828 [TBL] [Abstract][Full Text] [Related]
53. The Role of Biologic Therapies in Dermatology. Fathi R; Armstrong AW Med Clin North Am; 2015 Nov; 99(6):1183-94. PubMed ID: 26476247 [TBL] [Abstract][Full Text] [Related]
54. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study. Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799 [No Abstract] [Full Text] [Related]
55. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line. Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194 [TBL] [Abstract][Full Text] [Related]
56. The therapeutic potential of TNF-α antagonists in toxic epidermal necrosis: insights from two cases and adverse event reports. Vural S; Arakawa A; Arakawa Y; Prinz JC J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):e418-e419. PubMed ID: 29705991 [No Abstract] [Full Text] [Related]
57. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis. Gualdi G; Monari P; Rossi MT; Crotti S; Calzavara-Pinton PG Br J Dermatol; 2012 Jun; 166(6):1373-4. PubMed ID: 22212112 [No Abstract] [Full Text] [Related]
58. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792 [TBL] [Abstract][Full Text] [Related]
59. High frequency of cholestasis in generalized pustular psoriasis: Evidence for neutrophilic involvement of the biliary tract. Viguier M; Allez M; Zagdanski AM; Bertheau P; de Kerviler E; Rybojad M; Morel P; Dubertret L; Lémann M; Bachelez H Hepatology; 2004 Aug; 40(2):452-8. PubMed ID: 15368450 [TBL] [Abstract][Full Text] [Related]
60. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review. Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]